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Novelty and Impact 
This cohort study (N=39,900) of mortality in incident cancer patients sheds light on how statin and/or 
metformin usage is associated with all-cause and cause-specific mortality. An association between baseline 
statin usage and lower all-cause, cancer, and cardiovascular mortality was modified by cancer type. The 
effect of statin use was largest for breast and colorectal cancer. The association between metformin usage 
and lower mortality was strongest for liver, colorectal, and breast cancer. 
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 Abstract 
 
Both diabetes mellitus (DM) and cancer are common diseases and they frequently occur in the same 
patients. We investigated the all-cause and cause-specific mortality dynamics in relation to baseline DM, 
statin use, and metformin use. The study population consisted of 39,900 incident cancer cases from 
Finland, 19,822 patients were free of DM at the start of follow-up, and 20,078 had DM. Mortality from all 
causes, and cancer, cardiovascular (CVD) and other causes was analysed using Poisson regression model 
with the following variables: sex, age, DM, statin and metformin usage in baseline, cancer type and stage, 
and calendar period. Statin usage was associated with a reduced cancer-specific mortality with incidence 
rate ratio (IRR) 0.72 (95% confidence interval 0.69-0.74), IRR for CVD mortality was 0.95 (0.88-1.02), and for 
other causes 0.64 (0.56-0.74). In a sub-population of DM patients, IRR for metformin in all-cause mortality 
was 0.74 (0.71-0.78), in cancer mortality 0.75 (0.72-0.79), in CVD mortality 0.75 (0.68-0.83), and other 
causes 0.68 (0.60-0.78).  In conclusion, our register-based study of survival after cancer diagnosis showed 
that patients with diabetes had substantially poorer outcome in all measures. An association between 
baseline statin usage and lower all-cause, cancer, and cardiovascular mortality was modified by cancer 
type. The effect of statin use was largest for breast and colorectal cancer. Metformin usage in a 
subpopulation of oral antidiabetic users was in general associated with lower mortality, but this association 
was modified by cancer type.  The association was strongest for liver, colorectal, and breast cancer. 
 
 
 
Introduction 
 
Both diabetes mellitus (DM) and cancer are common diseases and they frequently occur in the same 
patients. It has been estimated that overall about 35% of population will develop diabetes in their lifetime 
and 44% cancer1, and about 15% both according to study of Danish population between 1995 and 2012. 
The overwhelmingly dominant cause of death  for general population and diabetics is due to cardiovascular 
disease 2.  The association between diabetes and cancer is well established in terms of both cancer 
incidence and mortality3–5. According  to a comprehensive meta-analysis (N=110,489), cancer patients with 
pre-existing diabetes have higher mortality (hazard rate (HR) 1.41; 95% confidence interval 1.28-1.55)  
compared to those without diabetes6. Highest risks of cancer death in relation to diabetes were in 
endometrial (HR 1.76; 1.34-2.31), breast (HR, 1.61; 1.46-1.78), and colorectal cancer (HR, 1.32; 1.24-1.41). 
In a pooled meta-analysis of incidence , population risk ratios  for overall cancer mortality (RR) 0.97 (0.75-
1.25) for men and 1.29 (1.16-1.44) for women was reported7. In a meta-analysis of 274,677 prostate cancer 
patients, cancer-specific mortality (RR 1.29; 1.22-1.38), and all-cause mortality (RR 1.37; 129-1.45) were 
increased in patients with diabetes.  
Prognostic factors in concurrent diabetes and cancer are numerous: the diabetes-associated co-morbidities 
like cardiovascular  disease or renal impairment may affect the therapeutic arsenal, antihyperglycemic 
therapy like metformin may decrease and insulin may increase the risk of cancer-progression, diabetic 
hyperglycemia may increase the infectious complications and cancer treatment may impair metabolic 
control of diabetes, thus further impairing the prognosis8. Due to increased risk of complications, diabetic 
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cancer patients may be  treated less aggressively than those without diabetes, which may contribute to 
worse survival9.   
Statin therapy is frequently used in diabetic patients for the prevention of cardiovascular complications, but 
a recent large meta-analysis showed that statin therapy was associated with reduced cancer-specific 
mortality as well (HR 0.60, 0.47-0.77)10. On the other hand, recently some observational studies11 and 
clinical trials12,13 have not detected any effect on survival. Thus, the prognosis in diabetic patient with 
cancer is driven by several factors and cardiovascular and cancer-specific causes being the main competing 
causes.  
We investigated the all-cause and cause-specific mortality dynamics in relation to baseline DM, usage of 
statins, and baseline usage of metformin. Our focus is on association between mortality and statin and 
antidiabetic medication in a large population with incident cancer.  
 
Material and methods 
 
Study population 
 
The study population was constructed based on the CARING Project 14 in Finland (Figure 1). The initial 
population consisted of two groups: 1) Individuals in the insulin group had purchased and received 
reimbursement for at least one insulin prescription (ATC code A10A) 15  between 01-01-1997 and 31-12-
2010; 2) The oral antidiabetic (OAD) group consisted of a 50% random sample of the people who had 
purchased and been reimbursed for at least one prescription of oral antidiabetic medication (A10B) in the 
same period. Initially, there were 170,052 individuals in the insulin group and 145,339 in the OAD group. 
Because of missing information (due to e.g. emigration), the final study population consisted of 314,353 
people (insulin and OAD groups). The proportion of participants with missing information was low (0.32%), 
and thus, it is not probable that results are very much affected. The date of the first purchase (insulin or 
OAD) was defined as the index date for an individual. One control subject with same sex, same birth year, 
and same hospital district and who was alive at the index date was selected for each exposed study subject. 
In the final study population, there were 169,398 individuals with insulin and 144,955 people with OAD, 
and the same number of controls for both groups. Insulin users may have been using OAD at the start of 
follow-up. The data of purchased and reimbursed medications were obtained for both groups from the 
Finnish Prescription Register and Finnish Registry for Reimbursed Medication maintained by the Social 
Insurance Institution of Finland (KELA). 
 
Follow-up and endpoint events 
 
For  the above mentioned study population, information on cancer diagnoses was obtained from the 
Finnish Cancer Registry (FCR)16. The data contained all cancer diagnoses starting from the year 1953. Stage 
was classified as local, regional, metastatic or unknown. In the construction of the study population for 
cancer survival, the inclusion criterion was having the first cancer diagnosis between 01-01-1996 and 31-12-
2010. The following exclusion criteria were used: 1) any cancer diagnosed before the index date of the 
participant; 2) any cancer diagnosis before 01-01-1996.  Non-melanoma skin cancers were not included in 
the cancer data. The criterion 1) was applied in order to avoid immortal time bias.  
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Follow-up for survival started at the diagnosis date of the first cancer, and ended at death or the common 
censoring date (31-12-2012), whichever occurred first (Appendix).   
The following data were available for the study population: date of birth, sex, the date of the first cancer 
diagnosis, cancer diagnosis according to the ICD-O-3 coding 17, date of death, cause of death (ICD-10 code), 
and information of prescriptions (date, ATC code, amount purchased) between 01-01-1996 and 31-12-2010 
for insulins, OAD, and statins (C10A). We formed the following four categories for diabetes, based on 
prescribed medication at the start of follow-up: no diabetes; on oral antidiabetics (OAD) only; using both 
OAD and insulin; and on insulin only. 
The cancer types included were: pancreas (ICD-O-3 topography code C25), lung (C33, C34), skin melanoma 
(C44), colorectal (C18, C19, C20), liver (C22), bladder (C67), breast (C50), corpus uteri (C54), prostate (C61), 
Non-Hodgkin lymphoma (morphological codes M959, M960- M964, M967- M969, M970- M972) (NHL), and 
other. Medication use (no/yes) was determined for the date of diagnosis i.e. start of follow-up using 
prescription information. 
Causes of death data were retrieved from Statistics Finland, where the vital status is collected for all Finnish 
citizens into the Finnish Causes of Death Register (FCDR)—irrespective of whether they die in Finland or 
abroad18. The cause of death data contained information about underlying and other causes of death. 
The primary outcome was death after cancer diagnosis. Secondary outcomes included death from cancer 
(ICD10 C00-C97), from cardiovascular diseases (CVD) (F01, G45, I00-I99, Q20, Q28, R96), or other causes. 
Deaths were classified by underlying cause. 
Statistical methods 
We modelled all-cause and cause-specific (CS) mortalities using Poisson regression models with sex, age, 
calendar year at start of follow-up, diabetes group, statin usage, metformin usage, stage, and cancer type 
as independent variables. Modelling CS is suited for addressing etiologic questions, as discussed by Austin 
et al.19.  Incidence rate ratios (IRR) were calculated using a log link function. Interactions were tested with 
likelihood ratio test. Poisson regression was chosen as statistical model, because it does not require an 
assumption of proportional hazards that is necessary with Cox’s proportional hazards model. As sensitivity 
analyses we carried out Poisson regression analyses with inverse probability treatment weights (IPTW) for 
statins20. Weights were calculated with sex, age, diabetes, and calendar period in denominator, and with 
intercept in numerator. 
We controlled for confounding using background variables as model covariates. All data-analyses were 
carried out using R language21 with package Epi22 and timereg23.  
 
Results 
 
The study population consisted of 39,900 individuals. During the follow-up, 125,376 person-years were 
cumulated with a mean follow-up time of 3.1 years and a median 2.0 years. The number of deaths was 
23,620.  About half of the study population were men (57 %) (Table 1). Of the subjects, 24% were on oral 
antidiabetic medication (OAD), 15% on OAD and insulin, and 11% used only insulin at the date of diagnosis 
(start of follow-up). More than half (61%) were over 70 years of age, 28% used a statin, and 25% metformin 
at baseline. The most frequently used statins were simvastatin (63% of the users) and atorvastatin (18%). 
There were 23,498 subjects without statin and metformin treatment, 6376 with statin but not metformin, 
5242 with metformin but not statin, and 4784 on both statin and metformin. 
Page 4 of 24International Journal of Cancer
All-cause mortality was highest in pancreas (165 per 100 person-years, 95% confidence interval 158-172) 
and liver (116, 95% CI 109-125) cancers. The lowest all-cause mortality was in breast (7.3, 95% CI 6.9-7.6) 
and prostate cancer (8.4, 95% CI 8.1-8.7). Cancer was the predominant cause of death (contributing at least 
half of the total mortality) in all cancer types, except skin melanoma and prostate cancer. The cancer types 
with the highest cancer-specific mortality had also the highest all-cause mortality, and vice versa (Table 2, 
Appendix Table 5). 
It was also evident and expected that non-diabetic people had considerably lower all-cause and cause-
specific mortality (Appendix Figure 2). However, because the use of the Kaplan-Meier survival function 
results in estimates of incidence that are biased upward19, we estimated also cumulative mortality 
functions. Cumulative mortality functions showed clearly that cancer was the leading cause of death in all 
study groups defined by diabetes (Appendix Figures 3). Considerable differences in unadjusted sub-
distribution mortality functions according to cancer types were observed when cancer, CVD, and other 
causes of death were analyzed (Figure 2). Pancreas, lung, and liver cancers showed the highest cancer 
mortalities, but the lowest CVD mortalities. Melanoma, bladder, and prostate cancers were associated with 
the highest CVD mortality rates. 
Analyses of all-cause mortality revealed that all diabetic groups had poorer survival compared to non-
diabetic subjects (Table 2). However, among people with DM, there was no differences between OAD only, 
combined OAD and insulin, and insulin only groups.   Statin use at the start of follow-up was associated 
with a lower all all-cause mortality (IRR 0.73, 0.71-0.75). Hormone-related cancers, breast and prostate, 
showed the lowest all-cause mortalities.  
Statin usage and mortality 
In the cause-specific analysis (Poisson regression) of cancer mortality, statin usage was associated with a 
reduced cancer-specific mortality (IRR 0.72, 0.69-0.74), for CVD mortality IRR was 0.95 (0.88-1.02), and for 
other causes 0.64 (0.56-0.74) (Table 3).  
Cardiovascular disease (CVD) mortality was more than twice as high for the diabetic group compared to the 
non-diabetic subjects. IRR for insulin-only diabetic patients was as high as 2.99 (2.71-3.27).  Statin usage at 
the start of the follow-up was not associated with CVD mortality in the cause-specific model.  
We observed a significant interaction between cancer type and statin for all-cause (χ2=27.372, df=10, 
p=0.0022), cancer (χ2=20.834, df=10, p=0.02228), and CVD mortality (χ2=21.728, df=10, p=0.01655) (Figure  
3A, Appendix Table 1). Results of the interaction model were quite similar to the stratified analyses (Table 
2). In all-cause mortality, statin use was associated with lower mortality for pancreas, lung, colorectal, 
breast, and other cancers. In cancer mortality for pancreas, colorectal, and other cancers, lower mortality 
was detected for statin users.  In CVD mortality, lower risk for statin users were found in breast cancer (IRR 
0.35, 0.18-0.68) and cancer of corpus uteri (0.48, 0.23-0.99). We tested for an interaction between diabetes 
and statin usage, but no interaction was detected for all-cause, or cause-specific mortalities. Thus, diabetes 
did not modify the effect of statin use. We also checked interactions between statin usage and stage, and 
no interactions were detected for all-cause, or cause-specific mortalities. IPTW analyses did not change 
results materially (Appendix Table 4). 
 In more detailed analyses of cause-specific mortality by type of statin, atorvastatin and lovastatin were 
associated with the lowest cancer mortality, though the differences between the agents were not large 
(Appendix Table 2). 
Metformin usage and mortality in diabetic subpopulation 
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We analyzed the association between mortality and the use of metformin at the start of the follow-up 
including only subjects with any oral antidiabetic medication (“OAD only “and “OAD and insulin” groups). 
The IRR for metformin in all-cause mortality was 0.74 (0.71-0.78), for cancer mortality 0.75 (0.72-0.79), for 
CVD mortality 0.75 (0.68-0.83), and other causes 0.68 (0.60-0.78).  Significant interactions between cancer 
type and statin were detected for these end-points [All-cause (χ2= 25.893, df=10, p= 0.003887), cancer 
mortality (χ2= 25.328, df=10, p= 0.004758) (Figure 3B, Appendix Table 3)].  
Discussion 
The aim of our study was to investigate the survival dynamics in diabetic patients with different glucose-
lowering treatments after cancer diagnosis as compared to non-diabetic subjects, and the modifying effects 
of statin and metformin usage. We focused our analyses on all-cause mortality, examining also separately 
competing causes of death including cancer, cardiovascular diseases, and other causes.   
Our results  confirm the earlier observations that diabetes is associated with a poorer survival after cancer 
diagnosis 4–7.  In patients with diabetes, both types of analyses yielded a consistent pattern of results: 
cancer patients with a pre-existing diabetes have poorer outcome, with generally the largest effects among 
the patients on insulin only.  
The main findings associate statin usage to lower mortality in nearly all models, and this association was 
not modified by diabetes.  Our results are in line with a population-based (N=3638) study of lung cancer 
survival reporting a hazard ratio (HR) 0.91 (0.80-1.02, P=0.10) for all-cause mortality24. In contrast, in 
colorectal cancer no association between statin use and survival was detected25.  In a nationwide cohort 
study of cancer patients, HR for statin users, as compared with patients who had never used statins, was 
0.85 (0.83-0.87) for all-cause mortality26. The study reported also cancer mortality for 27 cancer types, of 
which 13 showed a reduced mortality in statin users. The HR for death from cancer among statin users 
ranged from 0.64 (0.46-0.88) for cervical cancer to 0.89 (0.81 -0.98) for pancreatic cancer. In a clinical trial 
of simvastatin combined with FOLFIRI/XELIRi for patients with metastatic colorectal cancer, no mortality 
reduction was detected12. A similar result was also observed in an observational study in stage III colon 
cancer11. This raises a question if the observed effect of statin use in this study is at least partly due to 
confounding. In a trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer, no 
effect on overall survival was detected13. In subpopulation of our study subpopulation analyses with 445 
small cell lung cancers cases likewise gave similar result, no association between statin usage and all-cause 
mortality was observed. These discrepancies between observational and   clinical studies raises the 
question if the observed effect (s) of statin in this  and previous studies are at least partly explained by 
residual confounding  factors, that are difficult to capture in these kind of settings. 
Our population-level findings of statins are supported by recent results from a cell biological experiment, 
where administration of atorvastatin or rosuvastatin significantly reduced tumor growth in mice27. The 
results were obtained with doses, which were only slightly higher than the prescribed clinical dosage in 
humans. 
We checked the effect of metformin usage on all-cause and cause-specific mortality in the subpopulation of 
oral antidiabetic users. It turned out that metformin usage was associated with a lower mortality in all-
cause and cause specific mortality compared to no metformin usage. However, the association was 
modified by cancer type. The largest effect was detected for liver, colorectal, and breast cancer in all-cause 
mortality. As metformin is the recommended primary medication for new-onset type 2 diabetes in all major 
treatment guidelines 28, these patients likely had a shorter duration of diabetes and fewer complications 
Page 6 of 24International Journal of Cancer
than those on insulin. Type 2 diabetic patients not treated with metformin may have characteristics that 
somehow associate also with impaired survival, which may have caused selection bias or confounding by 
indication. These complications may be gastrointestinal disturbances and renal impairment, which are the 
most common reasons for discontinuing metformin treatment.  It is also possible that metformin has tumor 
suppressive effects that may be based on its metabolic effects 29,3031 32. In the Women’s Health Initiative 
study, long-term metformin use was associated with a lower risk of cancer death compared to other 
antidiabetic medication 33  in accordance with our results.   
The key limitation of this study is the lack of information about major prognostic factors for cancer survival 
including treatment, grade of differentiation and other comorbidities, which may result in residual 
confounding. The register data did not allow us to separate type 1 and type 2 diabetes in detail: those 
treated with oral drugs only or oral drugs and insulin were assumed to represent type 2 diabetes, whereas 
among those treated with insulin only the distinction was not possible. However, the large majority of the 
cases in the older age groups have type 2 diabetes. Because we did not use medication use as a time-
dependent predictor, it is possible that use of statin and metformin may have changed during the follow-
up.  We did not have data of socio-economic status or education that have shown to have effect on cancer  
survival34–37. However, at least in case of breast cancer no differences were detected in recent study of 
European countries38. Our Finnish study population is racially and ethnically fairly homogeneous, which 
may limit the generalizability of the results.   
The relatively large size of the study population, long follow-up period, and inclusion of both non-diabetic 
and diabetic individuals in the unselected, nationwide cohort are the strengths of our study.   
In conclusion, our register-based study of survival after cancer diagnosis showed that patients with 
diabetes had substantially poorer outcome according to all measures. An association between baseline 
statin usage and lower all-cause, cancer, and cardiovascular mortality was modified by cancer type. The 
effect of statin use was largest for breast and colorectal cancer. Metformin usage in a subpopulation of oral 
antidiabetic users was in general associated with a lower mortality, but this association was modified by 
cancer type.  The association was strongest for liver, colorectal, and breast cancer. 
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Table 1 Basic characteristics of the study population at start of follow-up. Number of participants, percentage by diabetes group in  parentheses. OAD: oral antidiabetics 
All no OAD only OAD and insulin insulin only 
All cancers All 39900 19822 9700 5824 4554
Sex male 22773 11339 (57.2%) 5503 (56.7%) 3287 (56.4%) 2644 (58.1%)
female 17127 8483 (42.8%) 4197 (43.3%) 2537 (43.6%) 1910 (41.9%)
Age 50 or under 1163 591 (3.0%) 140 (1.4%) 71 (1.2%) 361 (7.9%)
50-60 4015 1908 (9.6%) 838 (8.6%) 600 (10.3%) 669 (14.7%)
60-70 10277 4905 (24.7%) 2496 (25.7%) 1759 (30.2%) 1117 (24.5%)
Over 70 24445 12418 (62.6%) 6226 (64.2%) 3394 (58.3%) 2407 (52.9%)
Statin no 28740 16280 (82.1%) 6127 (63.2%) 3319 (57.0%) 3014 (66.2%)
yes 11160 3542 (17.9%) 3573 (36.8%) 2505 (43.0%) 1540 (33.8%)
Metformin no 29874 19822 (100.0%) 3485 (35.9%) 2013 (34.6%) 4554 (100.0%)
yes 10026 0 (0.0%) 6215 (64.1%) 3811 (65.4%) 0 (0.0%)
Stage unknown 8195 3975 (20.1%) 2002 (20.6%) 1226 (21.1%) 992 (21.8%)
localized 14643 7576 (38.2%) 3360 (34.6%) 2030 (34.9%) 1677 (36.8%)
Non-localized 17062 8271 (41.7%) 4338 (44.7%) 2568 (44.1%) 1885 (41.4%)
Pancreas 
Sex male 1078 343 (47.2%) 314 (51.2%) 251 (50.7%) 170 (56.1%) 
female 1059 383 (52.8%) 299 (48.8%) 244 (49.3%) 133 (43.9%) 
Age 50 or under 29 5 (0.7%) 9 (1.5%) 4 (0.8%) 11 (3.6%) 
50-60 207 55 (7.6%) 47 (7.7%) 55 (11.1%) 50 (16.5%) 
60-70 520 152 (20.9%) 151 (24.6%) 140 (28.3%) 77 (25.4%) 
Over 70 1381 514 (70.8%) 406 (66.2%) 296 (59.8%) 165 (54.5%) 
Statin no 1649 634 (87.3%) 447 (72.9%) 335 (67.7%) 233 (76.9%) 
yes 488 92 (12.7%) 166 (27.1%) 160 (32.3%) 70 (23.1%) 
Metformin no 1480 726 (100.0%) 246 (40.1%) 205 (41.4%) 303 (100.0%) 
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yes 657 0 (0.0%) 367 (59.9%) 290 (58.6%) 0 (0.0%) 
Stage unknown 440 136 (18.7%) 136 (22.2%) 95 (19.2%) 73 (24.1%) 
localized 172 56 (7.7%) 49 (8.0%) 40 (8.1%) 27 (8.9%) 
Non-localized 1525 534 (73.6%) 428 (69.8%) 360 (72.7%) 203 (67.0%) 
Lung 
Sex male 2803 1433 (77.2%) 672 (75.5%) 387 (75.0%) 311 (77.9%) 
female 858 423 (22.8%) 218 (24.5%) 129 (25.0%) 88 (22.1%) 
Age 50 or under 42 16 (0.9%) 5 (0.6%) 6 (1.2%) 15 (3.8%) 
50-60 340 146 (7.9%) 78 (8.8%) 52 (10.1%) 64 (16.0%) 
60-70 1072 523 (28.2%) 254 (28.5%) 170 (32.9%) 125 (31.3%) 
Over 70 2207 1171 (63.1%) 553 (62.1%) 288 (55.8%) 195 (48.9%) 
Statin no 2697 1576 (84.9%) 571 (64.2%) 291 (56.4%) 259 (64.9%) 
yes 964 280 (15.1%) 319 (35.8%) 225 (43.6%) 140 (35.1%) 
Metformin no 2782 1856 (100.0%) 348 (39.1%) 179 (34.7%) 399 (100.0%) 
yes 879 0 (0.0%) 542 (60.9%) 337 (65.3%) 0 (0.0%) 
Stage unknown 725 359 (19.3%) 179 (20.1%) 100 (19.4%) 87 (21.8%) 
localized 510 242 (13.0%) 120 (13.5%) 81 (15.7%) 67 (16.8%) 
Non-localized 2426 1255 (67.6%) 591 (66.4%) 335 (64.9%) 245 (61.4%) 
Melanoma 
Sex male 1567 802 (50.6%) 370 (55.3%) 226 (56.1%) 169 (58.1%) 
female 1381 783 (49.4%) 299 (44.7%) 177 (43.9%) 122 (41.9%) 
Age 50 or under 99 54 (3.4%) 11 (1.6%) 7 (1.7%) 27 (9.3%) 
50-60 216 110 (6.9%) 31 (4.6%) 39 (9.7%) 36 (12.4%) 
60-70 508 257 (16.2%) 126 (18.8%) 80 (19.9%) 45 (15.5%) 
Over 70 2125 1164 (73.4%) 501 (74.9%) 277 (68.7%) 183 (62.9%) 
Statin no 2008 1238 (78.1%) 392 (58.6%) 200 (49.6%) 178 (61.2%) 
yes 940 347 (21.9%) 277 (41.4%) 203 (50.4%) 113 (38.8%) 
Metformin no 2248 1585 (100.0%) 233 (34.8%) 139 (34.5%) 291 (100.0%) 
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yes 700 0 (0.0%) 436 (65.2%) 264 (65.5%) 0 (0.0%) 
Stage unknown 1130 614 (38.7%) 247 (36.9%) 161 (40.0%) 108 (37.1%) 
 
localized 1571 834 (52.6%) 369 (55.2%) 205 (50.9%) 163 (56.0%) 
 
Non-localized 247 137 (8.6%) 53 (7.9%) 37 (9.2%) 20 (6.9%) 
 Colorectal 
    Sex male 2191 1015 (52.7%) 554 (55.6%) 325 (55.9%) 297 (59.0%) 
 
female 1817 912 (47.3%) 443 (44.4%) 256 (44.1%) 206 (41.0%) 
Age 50 or under 80 44 (2.3%) 9 (0.9%) 8 (1.4%) 19 (3.8%) 
 
50-60 351 150 (7.8%) 78 (7.8%) 55 (9.5%) 68 (13.5%) 
 
60-70 945 420 (21.8%) 236 (23.7%) 165 (28.4%) 124 (24.7%) 
 
Over 70 2632 1313 (68.1%) 674 (67.6%) 353 (60.8%) 292 (58.1%) 
Statin no 2835 1579 (81.9%) 637 (63.9%) 310 (53.4%) 309 (61.4%) 
 
yes 1173 348 (18.1%) 360 (36.1%) 271 (46.6%) 194 (38.6%) 
Metformin no 2972 1927 (100.0%) 351 (35.2%) 191 (32.9%) 503 (100.0%) 
 
yes 1036 0 (0.0%) 646 (64.8%) 390 (67.1%) 0 (0.0%) 
Stage unknown 607 268 (13.9%) 171 (17.2%) 88 (15.1%) 80 (15.9%) 
 
localized 1201 595 (30.9%) 274 (27.5%) 161 (27.7%) 171 (34.0%) 
 
Non-localized 2200 1064 (55.2%) 552 (55.4%) 332 (57.1%) 252 (50.1%) 
 Liver 
    Sex male 644 136 (58.6%) 208 (69.6%) 182 (71.7%) 118 (69.8%) 
 
female 310 96 (41.4%) 91 (30.4%) 72 (28.3%) 51 (30.2%) 
Age 50 or under 11 4 (1.7%) 0 (0.0%) 2 (0.8%) 5 (3.0%) 
 
50-60 93 16 (6.9%) 21 (7.0%) 29 (11.4%) 27 (16.0%) 
 
60-70 273 49 (21.1%) 84 (28.1%) 82 (32.3%) 58 (34.3%) 
 
Over 70 577 163 (70.3%) 194 (64.9%) 141 (55.5%) 79 (46.7%) 
Statin no 725 202 (87.1%) 229 (76.6%) 162 (63.8%) 132 (78.1%) 
 
yes 229 30 (12.9%) 70 (23.4%) 92 (36.2%) 37 (21.9%) 
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Metformin no 632 232 (100.0%) 119 (39.8%) 112 (44.1%) 169 (100.0%) 
yes 322 0 (0.0%) 180 (60.2%) 142 (55.9%) 0 (0.0%) 
Stage unknown 368 75 (32.3%) 123 (41.1%) 98 (38.6%) 72 (42.6%) 
localized 235 48 (20.7%) 74 (24.7%) 69 (27.2%) 44 (26.0%) 
Non-localized 351 109 (47.0%) 102 (34.1%) 87 (34.3%) 53 (31.4%) 
Bladder 
Sex male 1240 588 (79.7%) 310 (79.3%) 198 (79.5%) 144 (82.3%) 
female 313 150 (20.3%) 81 (20.7%) 51 (20.5%) 31 (17.7%) 
Age 50 or under 23 10 (1.4%) 5 (1.3%) 0 (0.0%) 8 (4.6%) 
50-60 109 44 (6.0%) 29 (7.4%) 16 (6.4%) 20 (11.4%) 
60-70 379 178 (24.1%) 91 (23.3%) 74 (29.7%) 36 (20.6%) 
Over 70 1042 506 (68.6%) 266 (68.0%) 159 (63.9%) 111 (63.4%) 
Statin no 1055 580 (78.6%) 224 (57.3%) 140 (56.2%) 111 (63.4%) 
yes 498 158 (21.4%) 167 (42.7%) 109 (43.8%) 64 (36.6%) 
Metformin no 1163 738 (100.0%) 147 (37.6%) 103 (41.4%) 175 (100.0%) 
yes 390 0 (0.0%) 244 (62.4%) 146 (58.6%) 0 (0.0%) 
Stage unknown 316 141 (19.1%) 82 (21.0%) 54 (21.7%) 39 (22.3%) 
localized 1054 505 (68.4%) 262 (67.0%) 168 (67.5%) 119 (68.0%) 
Non-localized 183 92 (12.5%) 47 (12.0%) 27 (10.8%) 17 (9.7%) 
Breast 
Sex male 33 15 (0.6%) 5 (0.5%) 7 (1.3%) 6 (1.2%) 
female 4255 2309 (99.4%) 952 (99.5%) 516 (98.7%) 478 (98.8%) 
Age 50 or under 260 150 (6.5%) 22 (2.3%) 10 (1.9%) 78 (16.1%) 
50-60 708 409 (17.6%) 126 (13.2%) 81 (15.5%) 92 (19.0%) 
60-70 1173 650 (28.0%) 252 (26.3%) 158 (30.2%) 113 (23.3%) 
Over 70 2147 1115 (48.0%) 557 (58.2%) 274 (52.4%) 201 (41.5%) 
Statin no 3146 1951 (84.0%) 584 (61.0%) 286 (54.7%) 325 (67.1%) 
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yes 1142 373 (16.0%) 373 (39.0%) 237 (45.3%) 159 (32.9%) 
Metformin no 3250 2324 (100.0%) 284 (29.7%) 158 (30.2%) 484 (100.0%) 
 
yes 1038 0 (0.0%) 673 (70.3%) 365 (69.8%) 0 (0.0%) 
Stage unknown 299 168 (7.2%) 51 (5.3%) 40 (7.6%) 40 (8.3%) 
 
localized 2157 1211 (52.1%) 459 (48.0%) 248 (47.4%) 239 (49.4%) 
 
Non-localized 1832 945 (40.7%) 447 (46.7%) 235 (44.9%) 205 (42.4%) 
 Corpus uteri 
 Sex female 1211 497 (100.0%) 358 (100.0%) 240 (100.0%) 116 (100.0%) 
Age 50 or under 23 9 (1.8%) 6 (1.7%) 4 (1.7%) 4 (3.4%) 
 
50-60 138 49 (9.9%) 41 (11.5%) 35 (14.6%) 13 (11.2%) 
 
60-70 336 139 (28.0%) 84 (23.5%) 79 (32.9%) 34 (29.3%) 
 
Over 70 714 300 (60.4%) 227 (63.4%) 122 (50.8%) 65 (56.0%) 
Statin no 803 397 (79.9%) 214 (59.8%) 129 (53.8%) 63 (54.3%) 
 
yes 408 100 (20.1%) 144 (40.2%) 111 (46.3%) 53 (45.7%) 
Metformin no 764 497 (100.0%) 99 (27.7%) 52 (21.7%) 116 (100.0%) 
 
yes 447 0 (0.0%) 259 (72.3%) 188 (78.3%) 0 (0.0%) 
Stage unknown 278 113 (22.7%) 84 (23.5%) 52 (21.7%) 29 (25.0%) 
 
localized 688 292 (58.8%) 182 (50.8%) 140 (58.3%) 74 (63.8%) 
 
Non-localized 245 92 (18.5%) 92 (25.7%) 48 (20.0%) 13 (11.2%) 
 Prostate 
 Sex male 7533 4276 (100.0%) 1679 (100.0%) 888 (100.0%) 690 (100.0%) 
Age 50 or under 26 11 (0.3%) 8 (0.5%) 1 (0.1%) 6 (0.9%) 
 
50-60 568 331 (7.7%) 107 (6.4%) 67 (7.5%) 63 (9.1%) 
 
60-70 2411 1345 (31.5%) 550 (32.8%) 313 (35.2%) 203 (29.4%) 
 
Over 70 4528 2589 (60.5%) 1014 (60.4%) 507 (57.1%) 418 (60.6%) 
Statin no 5088 3343 (78.2%) 908 (54.1%) 446 (50.2%) 391 (56.7%) 
 
yes 2445 933 (21.8%) 771 (45.9%) 442 (49.8%) 299 (43.3%) 
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Metformin no 5741 4276 (100.0%) 515 (30.7%) 260 (29.3%) 690 (100.0%) 
yes 1792 0 (0.0%) 1164 (69.3%) 628 (70.7%) 0 (0.0%) 
Stage unknown 1839 1019 (23.8%) 379 (22.6%) 244 (27.5%) 197 (28.6%) 
localized 4039 2314 (54.1%) 923 (55.0%) 462 (52.0%) 340 (49.3%) 
Non-localized 1655 943 (22.1%) 377 (22.5%) 182 (20.5%) 153 (22.2%) 
NHL 
Sex male 60 24 (49.0%) 12 (60.0%) 15 (65.2%) 9 (52.9%) 
female 49 25 (51.0%) 8 (40.0%) 8 (34.8%) 8 (47.1%) 
Age 50 or under 2 1 (2.0%) 1 (5.0%) 0 (0.0%) 0 (0.0%) 
50-60 11 3 (6.1%) 2 (10.0%) 2 (8.7%) 4 (23.5%) 
60-70 22 9 (18.4%) 3 (15.0%) 6 (26.1%) 4 (23.5%) 
Over 70 74 36 (73.5%) 14 (70.0%) 15 (65.2%) 9 (52.9%) 
Statin no 72 38 (77.6%) 13 (65.0%) 9 (39.1%) 12 (70.6%) 
yes 37 11 (22.4%) 7 (35.0%) 14 (60.9%) 5 (29.4%) 
Metformin no 87 49 (100.0%) 14 (70.0%) 7 (30.4%) 17 (100.0%) 
yes 22 0 (0.0%) 6 (30.0%) 16 (69.6%) 0 (0.0%) 
Stage unknown 55 27 (55.1%) 11 (55.0%) 10 (43.5%) 7 (41.2%) 
localized 26 11 (22.4%) 5 (25.0%) 7 (30.4%) 3 (17.6%) 
Non-localized 28 11 (22.4%) 4 (20.0%) 6 (26.1%) 7 (41.2%) 
Other 
Sex male 5624 2707 (48.2%) 1379 (48.8%) 808 (48.9%) 730 (51.9%) 
female 5874 2905 (51.8%) 1448 (51.2%) 844 (51.1%) 677 (48.1%) 
Age 50 or under 568 287 (5.1%) 64 (2.3%) 29 (1.8%) 188 (13.4%) 
50-60 1274 595 (10.6%) 278 (9.8%) 169 (10.2%) 232 (16.5%) 
60-70 2638 1183 (21.1%) 665 (23.5%) 492 (29.8%) 298 (21.2%) 
Over 70 7018 3547 (63.2%) 1820 (64.4%) 962 (58.2%) 689 (49.0%) 
Statin no 8662 4742 (84.5%) 1908 (67.5%) 1011 (61.2%) 1001 (71.1%) 
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yes 2836 870 (15.5%) 919 (32.5%) 641 (38.8%) 406 (28.9%) 
Metformin no 8755 5612 (100.0%) 1129 (39.9%) 607 (36.7%) 1407 (100.0%) 
 
yes 2743 0 (0.0%) 1698 (60.1%) 1045 (63.3%) 0 (0.0%) 
Stage unknown 2138 1055 (18.8%) 539 (19.1%) 284 (17.2%) 260 (18.5%) 
 
localized 2990 1468 (26.2%) 643 (22.7%) 449 (27.2%) 430 (30.6%) 
 
Non-localized 6370 3089 (55.0%) 1645 (58.2%) 919 (55.6%) 717 (51.0%) 
  
Page 17 of 24 International Journal of Cancer
Table 2 All-cause and cause-specific mortality rate ratios. Stratified analyses by cancer type. All analyses are adjusted for sex, age, diabetes (DM), statin medication, stage, and calendar period 
using multivariate Poisson model. NA=not available. 
Pancreas 
All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.94 (0.86 - 1.03) 0.96 (0.88 - 1.06) 0.38 (0.20 - 0.71) 0.85 (0.46 - 1.56) 
Age (per 1 year) 1.04 (1.04 - 1.05) 1.04 (1.04 - 1.05) 1.10 (1.07 - 1.15) 1.08 (1.04 - 1.11) 
DM (ref. no DM) OAD only 1.14 (1.02 - 1.27) 1.15 (1.03 - 1.29) 0.94 (0.42 - 2.11) 0.96 (0.44 - 2.12) 
OAD and insulin 1.20 (1.07 - 1.35) 1.18 (1.04 - 1.33) 2.48 (1.19 - 5.16) 1.25 (0.56 - 2.81) 
insulin only 1.29 (1.12 - 1.48) 1.26 (1.09 - 1.45) 1.27 (0.45 - 3.62) 2.45 (1.13 - 5.31) 
Statin (ref. no)  yes 0.85 (0.76 - 0.94) 0.83 (0.74 - 0.92) 2.16 (1.09 - 4.27) 0.93 (0.45 - 1.92) 
Stage (ref. unknown) localized 0.56 (0.47 - 0.67) 0.55 (0.45 - 0.67) 0.81 (0.35 - 1.90) 0.69 (0.32 - 1.51) 
non-localized 1.29 (1.15 - 1.44) 1.37 (1.22 - 1.54) 0.54 (0.28 - 1.05) 0.29 (0.15 - 0.56) 
Lung All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.86 (0.79 - 0.93) 0.89 (0.82 - 0.97) 0.54 (0.38 - 0.77) 0.87 (0.58 - 1.32) 
Age (per 1 year) 1.04 (1.04 - 1.04) 1.04 (1.03 - 1.04) 1.07 (1.05 - 1.09) 1.07 (1.04 - 1.09) 
DM (ref. no DM) OAD only 1.20 (1.10 - 1.30) 1.17 (1.07 - 1.28) 1.45 (1.03 - 2.03) 1.43 (0.93 - 2.20) 
OAD and insulin 1.10 (0.99 - 1.23) 1.07 (0.96 - 1.20) 1.50 (0.99 - 2.28) 1.43 (0.82 - 2.49) 
insulin only 1.49 (1.33 - 1.67) 1.38 (1.22 - 1.56) 3.02 (2.07 - 4.42) 1.97 (1.14 - 3.43) 
Statin (ref. no)  yes 0.75 (0.69 - 0.82) 0.74 (0.68 - 0.81) 1.03 (0.75 - 1.41) 0.62 (0.39 - 0.98) 
Stage (ref. unknown) localized 0.40 (0.35 - 0.46) 0.35 (0.30 - 0.40) 0.76 (0.54 - 1.07) 0.61 (0.40 - 0.95) 
non-localized 1.63 (1.49 - 1.78) 1.83 (1.66 - 2.01) 0.71 (0.51 - 0.98) 0.46 (0.30 - 0.70) 
Melanoma All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.86 (0.77 - 0.96) 0.73 (0.60 - 0.90) 0.95 (0.81 - 1.13) 0.81 (0.64 - 1.03) 
Age (per 1 year) 1.07 (1.06 - 1.08) 1.02 (1.02 - 1.03) 1.11 (1.10 - 1.12) 1.09 (1.07 - 1.10) 
DM (ref. no DM) OAD only 1.31 (1.14 - 1.51) 1.05 (0.80 - 1.36) 1.50 (1.23 - 1.83) 1.31 (0.98 - 1.73) 
OAD and insulin 1.64 (1.39 - 1.93) 1.26 (0.93 - 1.69) 2.37 (1.88 - 2.98) 1.14 (0.76 - 1.71) 
insulin only 1.96 (1.64 - 2.35) 1.38 (0.99 - 1.92) 2.23 (1.70 - 2.92) 2.33 (1.63 - 3.31) 
Statin (ref. no)  yes 0.84 (0.73 - 0.96) 0.81 (0.63 - 1.03) 1.05 (0.86 - 1.29) 0.66 (0.48 - 0.90) 
Stage (ref. unknown) localized 0.92 (0.82 - 1.04) 0.64 (0.50 - 0.82) 1.00 (0.85 - 1.19) 1.15 (0.90 - 1.46) 
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non-localized 3.80 (3.16 - 4.57) 8.31 (6.48 - 10.66) 1.14 (0.71 - 1.82) 0.82 (0.38 - 1.77) 
Colorectal All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.78 (0.72 - 0.85) 0.87 (0.78 - 0.96) 0.57 (0.47 - 0.70) 0.72 (0.56 - 0.94) 
Age (per 1 year) 1.06 (1.06 - 1.07) 1.05 (1.05 - 1.06) 1.10 (1.08 - 1.11) 1.06 (1.04 - 1.08) 
DM (ref. no DM) OAD only 1.31 (1.19 - 1.46) 1.24 (1.10 - 1.40) 1.62 (1.28 - 2.05) 1.31 (0.94 - 1.84) 
OAD and insulin 1.34 (1.18 - 1.51) 1.11 (0.95 - 1.30) 2.04 (1.56 - 2.69) 2.08 (1.45 - 3.00) 
insulin only 1.93 (1.71 - 2.19) 1.39 (1.18 - 1.63) 3.85 (2.99 - 4.95) 3.28 (2.32 - 4.64) 
Statin (ref. no)  yes 0.68 (0.62 - 0.76) 0.66 (0.58 - 0.74) 0.96 (0.77 - 1.19) 0.47 (0.33 - 0.67) 
Stage (ref. unknown) localized 0.53 (0.46 - 0.60) 0.37 (0.30 - 0.44) 0.76 (0.60 - 0.95) 0.72 (0.53 - 0.99) 
non-localized 1.65 (1.47 - 1.84) 2.33 (2.01 - 2.69) 0.73 (0.57 - 0.94) 0.59 (0.42 - 0.84) 
Liver All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 1.11 (0.96 - 1.29) 1.20 (1.03 - 1.41) 0.62 (0.30 - 1.27) 0.48 (0.23 - 0.98) 
Age (per 1 year) 1.03 (1.02 - 1.04) 1.04 (1.03 - 1.04) 1.05 (1.02 - 1.09) 1.00 (0.97 - 1.02) 
DM (ref. no DM) OAD only 1.04 (0.86 - 1.25) 1.09 (0.90 - 1.32) 0.62 (0.27 - 1.43) 0.69 (0.33 - 1.42) 
OAD and insulin 1.06 (0.88 - 1.29) 1.11 (0.91 - 1.36) 0.55 (0.22 - 1.38) 0.90 (0.45 - 1.84) 
insulin only 1.11 (0.90 - 1.38) 1.05 (0.83 - 1.32) 1.66 (0.74 - 3.74) 1.10 (0.53 - 2.27) 
Statin (ref. no)  yes 0.83 (0.70 - 0.98) 0.87 (0.73 - 1.04) 0.88 (0.40 - 1.95) 0.34 (0.15 - 0.78) 
Stage (ref. unknown) localized 0.53 (0.44 - 0.63) 0.50 (0.41 - 0.61) 0.70 (0.36 - 1.35) 0.70 (0.40 - 1.21) 
non-localized 1.68 (1.44 - 1.96) 1.86 (1.58 - 2.19) 0.62 (0.27 - 1.43) 0.65 (0.32 - 1.30) 
Bladder All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.93 (0.78 - 1.10) 1.07 (0.85 - 1.35) 0.61 (0.43 - 0.86) 1.23 (0.82 - 1.83) 
Age (per 1 year) 1.07 (1.06 - 1.08) 1.05 (1.04 - 1.06) 1.09 (1.08 - 1.11) 1.08 (1.06 - 1.10) 
DM (ref. no DM) OAD only 1.47 (1.23 - 1.76) 1.46 (1.15 - 1.86) 1.79 (1.29 - 2.49) 1.09 (0.68 - 1.75) 
OAD and insulin 1.85 (1.52 - 2.27) 1.74 (1.31 - 2.31) 2.52 (1.78 - 3.56) 1.21 (0.70 - 2.10) 
insulin only 2.18 (1.76 - 2.70) 1.39 (0.99 - 1.96) 3.07 (2.14 - 4.40) 3.15 (2.01 - 4.94) 
Statin (ref. no)  yes 0.77 (0.64 - 0.92) 0.69 (0.53 - 0.88) 1.17 (0.86 - 1.58) 0.41 (0.24 - 0.70) 
Stage (ref. unknown) localized 0.61 (0.52 - 0.72) 0.57 (0.44 - 0.73) 0.65 (0.49 - 0.85) 0.65 (0.44 - 0.96) 
non-localized 3.51 (2.82 - 4.37) 6.47 (4.90 - 8.56) 0.82 (0.43 - 1.55) 0.74 (0.31 - 1.76) 
Breast All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Age (per 1 year) 1.07 (1.07 - 1.08) 1.05 (1.04 - 1.05) 1.12 (1.11 - 1.13) 1.09 (1.08 - 1.10) 
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DM (ref. no DM)  OAD only 1.48 (1.30 - 1.69) 1.32 (1.11 - 1.58) 1.82 (1.42 - 2.34) 1.57 (1.17 - 2.10) 
  OAD and insulin 1.78 (1.53 - 2.08) 1.28 (1.02 - 1.60) 2.98 (2.27 - 3.91) 1.90 (1.35 - 2.68) 
  insulin only 2.00 (1.71 - 2.35) 1.40 (1.11 - 1.77) 3.43 (2.59 - 4.53) 1.95 (1.35 - 2.82) 
Statin (ref. no)  yes 0.66 (0.57 - 0.76) 0.71 (0.59 - 0.86) 0.61 (0.47 - 0.80) 0.69 (0.50 - 0.95) 
Stage (ref. unknown) localized 0.47 (0.39 - 0.56) 0.30 (0.23 - 0.40) 0.76 (0.56 - 1.04) 0.56 (0.39 - 0.80) 
  non-localized 1.04 (0.88 - 1.24) 1.35 (1.05 - 1.74) 0.91 (0.66 - 1.26) 0.61 (0.42 - 0.89) 
Corpus uteri   All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Age (per 1 year) 1.09 (1.08 - 1.10) 1.08 (1.07 - 1.10) 1.12 (1.09 - 1.14) 1.08 (1.05 - 1.12) 
DM (ref. no DM)  OAD only 1.46 (1.16 - 1.84) 1.21 (0.91 - 1.62) 1.75 (1.08 - 2.84) 2.70 (1.31 - 5.54) 
  OAD and insulin 2.30 (1.80 - 2.94) 1.65 (1.19 - 2.29) 3.87 (2.44 - 6.12) 3.57 (1.68 - 7.59) 
  insulin only 2.09 (1.52 - 2.86) 1.07 (0.65 - 1.76) 3.81 (2.23 - 6.51) 5.09 (2.29 - 11.32) 
Statin (ref. no)  yes 0.80 (0.63 - 1.00) 0.82 (0.61 - 1.10) 0.95 (0.62 - 1.47) 0.59 (0.30 - 1.17) 
Stage (ref. unknown) localized 0.77 (0.60 - 0.97) 0.68 (0.48 - 0.96) 0.80 (0.54 - 1.18) 1.01 (0.55 - 1.86) 
  non-localized 3.37 (2.61 - 4.35) 5.44 (3.91 - 7.58) 1.14 (0.63 - 2.04) 0.87 (0.31 - 2.45) 
Prostate   All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Age (per 1 year) 1.08 (1.08 - 1.09) 1.06 (1.05 - 1.07) 1.10 (1.09 - 1.11) 1.10 (1.09 - 1.11) 
DM (ref. no DM)  OAD only 1.47 (1.34 - 1.62) 1.18 (1.02 - 1.36) 1.77 (1.51 - 2.07) 1.73 (1.40 - 2.12) 
  OAD and insulin 1.98 (1.77 - 2.21) 1.47 (1.23 - 1.75) 2.60 (2.18 - 3.10) 2.21 (1.73 - 2.83) 
  insulin only 1.98 (1.76 - 2.23) 1.14 (0.93 - 1.40) 2.86 (2.38 - 3.44) 2.88 (2.26 - 3.67) 
Statin (ref. no)  yes 0.84 (0.77 - 0.92) 0.82 (0.72 - 0.95) 1.02 (0.88 - 1.19) 0.61 (0.49 - 0.76) 
Stage (ref. unknown) localized 0.72 (0.66 - 0.79) 0.56 (0.48 - 0.66) 0.82 (0.71 - 0.94) 0.83 (0.69 - 1.00) 
  non-localized 1.73 (1.57 - 1.90) 3.02 (2.63 - 3.47) 1.04 (0.87 - 1.24) 0.79 (0.61 - 1.02) 
NHL    All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.93 (0.55 - 1.55) 1.20 (0.64 - 2.26) 0.55 (0.17 - 1.78) 0.54 (0.08 - 3.58) 
Age (per 1 year) 1.06 (1.03 - 1.09) 1.04 (1.01 - 1.08) 1.13 (1.05 - 1.22) 1.14 (0.97 - 1.34) 
DM (ref. no DM)  OAD only 2.06 (1.07 - 3.97) 2.63 (1.20 - 5.76) 1.17 (0.28 - 4.92) 1.25 (0.11 - 14.83) 
  OAD and insulin 0.73 (0.36 - 1.48) 0.69 (0.27 - 1.72) 0.61 (0.14 - 2.58) 2.05 (0.24 - 17.28) 
  insulin only 2.56 (1.26 - 5.20) 3.32 (1.45 - 7.64) 1.76 (0.36 - 8.62) NA  
Statin (ref. no)  yes 1.27 (0.68 - 2.38) 1.00 (0.46 - 2.15) 2.80 (0.73 - 10.80) 0.48 (0.03 - 7.14) 
Stage (ref. unknown) localized 1.45 (0.76 - 2.79) 1.24 (0.54 - 2.81) 3.61 (1.04 - 12.57) NA  
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  non-localized 3.46 (1.88 - 6.36) 4.29 (2.11 - 8.72) 1.37 (0.26 - 7.25) 2.39 (0.29 - 19.49) 
Other   All-cause mortality  Cancer mortality  CVD mortality  Other mortality 
Sex (ref. male) female 0.85 (0.82 - 0.89) 0.90 (0.85 - 0.94) 0.71 (0.62 - 0.80) 0.70 (0.59 - 0.81) 
Age (per 1 year) 1.06 (1.06 - 1.07) 1.06 (1.06 - 1.06) 1.09 (1.08 - 1.10) 1.07 (1.06 - 1.08) 
DM (ref. no DM)  OAD only 1.50 (1.42 - 1.58) 1.41 (1.33 - 1.50) 2.03 (1.74 - 2.38) 1.78 (1.46 - 2.16) 
  OAD and insulin 1.47 (1.37 - 1.57) 1.32 (1.23 - 1.42) 2.54 (2.14 - 3.03) 1.70 (1.35 - 2.15) 
  insulin only 1.64 (1.53 - 1.76) 1.38 (1.27 - 1.50) 3.04 (2.54 - 3.65) 2.81 (2.26 - 3.49) 
Statin (ref. no)  yes 0.67 (0.63 - 0.71) 0.65 (0.61 - 0.70) 0.87 (0.75 - 1.01) 0.53 (0.43 - 0.66) 
Stage (ref. unknown) localized 0.54 (0.50 - 0.58) 0.47 (0.43 - 0.51) 0.72 (0.62 - 0.85) 0.76 (0.61 - 0.93) 
  non-localized 1.81 (1.71 - 1.92) 2.18 (2.04 - 2.33) 0.80 (0.68 - 0.93) 1.04 (0.86 - 1.27) 
 
 
 
 
 
Page 21 of 24 International Journal of Cancer
Figure 1. Construction of study population. People with at least one purchase of oral antidiabetics (OAD) 
(50% random sample) and all insulin users between 1996 and 2010 in Finland were included in the exposed 
cohort. One control for each cohort member was matched by sex, birth year, and living area.  
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Figure 2. Cumulative mortality functions by cancer type for three competing causes of death: cancer, 
cardiovascular diseases (CVD), and other causes. Note different y-axis scales.  
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(A) Association between baseline statin usage and all-cause and cause-specific mortality by  cancer 
type.  IRR with 95% confidence intervals for all-cause mortality. All-cause (square), cancer (bullet), and 
CVD mortality (diamond).  All analyses are adjusted for sex, age, diabetes, stage, interaction between 
cancer type and statin usage, and calendar period with Poisson regression. %"%"(B)  Association between 
baseline metformin usage and all-cause and cause-specific mortality by cancer type. Only users of oral 
antidiabetics included.   IRR with 95% confidence intervals for all-cause mortality. All-cause (square) and 
cancer (bullet). All analyses are adjusted for sex, age, diabetes, stage, interaction between cancer type and 
metformin usage, and calendar period with Poisson regression. 
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